Extrait

Study hypothesis is that aprepitant is more effective than desloratadine in relieving pruritus caused by EGFR TKIs. Primary endpoint is the effective rate of pruritus, effective treatment defined as visual analogue scale (VAS) decrease ≥ 50% after treatment compared to baseline score. 130 NSCLC patients undertaken EGFR-TKI and suffer from moderate or severe pruritus (VAS score ≥ 4) will be enrolled in this study, and stratified (gender, first or seconde generation TKIs, VAS 4-6 or 7-10) randomized (1:1) into aprepitant or desloratadine treatment. VAS investigation will be taken once a week to treatment end or follow-up end (≤12 weeks).

Critère d'inclusion

• non-small cell lung cancer

Liens

• nct
• ictrp